CHINARES PHARMA(HK:03320) 智通财经网·2025-08-26 04:28Core Insights - China Resources Pharmaceutical (03320) reported a mid-year performance for 2025, achieving revenue of RMB 131.867 billion, a year-on-year increase of 2.54% [1] - The company's profit attributable to equity shareholders was RMB 2.077 billion, a decrease of 20.25% year-on-year, with earnings per share at RMB 0.33 and an interim dividend proposed at RMB 0.072 per share [1] - The gross profit for the reporting period was RMB 21.5096 billion, up 2.8% from RMB 20.934 billion in the same period last year, maintaining a gross margin of 16.3% [1] Revenue Breakdown - The revenue contributions from the three main business segments were 16.6% from pharmaceuticals, 79.2% from medical distribution, and 4.2% from retail and other operations [1] - The company has a total of 83 production bases and 561 production lines, producing 944 products, with 555 products included in the national medical insurance catalog and 235 products in the essential drug list [1] Profitability Metrics - Excluding the impact of impairment and other one-off items, the net profit for the reporting period saw a slight decline of 1.3%, while the profit attributable to the company's owners decreased by 4.7% year-on-year [1]